Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
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
Lq0w0cxy1rqbgcs2
